Exhibit 99.2

Investor Presentation December 2020

DISCLAIMER 2 This presentation has been prepared by LCP Edge Intermediate, Inc . and its affiliates (collectively, the “Company”) in connection with a proposed business combination involving the Company as further described herein (the “Transaction”) . This presentation has been prepared to assist interested parties in making their own evaluation with respect to the proposed Transaction and for no other purpose . This presentation is for informational purposes only and does not constitute an offer or invitation for the sale or purchase of the securities, assets or business described herein or a commitment of the Company with respect to any of the foregoing, and this presentation shall not form the basis of any contract . This presentation contains certain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange act of 1934, as amended. These statements may be made directly in this presentation. Some of the forward - looking statements can be identified by the use of forward - looking words. Statements that are not historical in nature, including the words “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions are intended to identify forward - looking statements. All forward - looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of the date of this presentation, and may include, without limitation, changes in general economic conditions as a result of COVID - 19, all of which are accordingly subject to change. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this presentation constitute the Company’s judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward - looking statements and projections contained in this presentation are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause the Company’s actual results, performance or financial condition to be materially different from the expectations of future results, performance of financial condition. Although such forward - looking statements have been made in good faith and are based on assumptions we believe to be reasonable, there is no assurance that the expected results will be achieved. The Company’s actual results may differ materially from the results discussed in forward - looking statements. In addition, the Company’s analyses contained herein are not, and do not purport to be, appraisals of the securities, assets or business of the Company or any other entity. Further, this presentation does not purport to contain all information that may be required or relevant to an evaluation of the Transaction. You will be responsible for conducting the investigations and analyses that you deems appropriate and for seeking independent counsel from your advisors in connection with the Transaction. The Company reserves the right to amend or replace this presentation at any time but none of the Company, its subsidiaries, affiliates, legal advisors or financial advisors shall have any obligation to update or supplement any content set forth in this presentation or otherwise provide any additional information in connection with the Transaction should circumstances, management's estimates or opinions change or any information provided in this presentation become inaccurate. The historical financial data included in this presentation is subject to audit completion. In addition, this presentation includes references to non - GAAP financial measures, including but not limited to Gross Margin, Adjusted Gross Margin and Adjusted EBITDA. Such non - GAAP measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP. Please see the reconciliation on slide 43. Additionally, to the extent that forward - looking non - GAAP financial measures are provided, they are presented on a non - GAAP basis without reconciliations of such forward - looking non - GAAP measures due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Certain financial information and projections contained in this presentation are in draft form and based on internal financial reports as of November 11, 2020. These figures may not include all adjustments required by GAAP under PCAOB standard. Neither the Company nor any of its directors, officers, employees, advisors, representatives or agents makes any representation or warranty of any kind, express or implied, as to the value that may be realized in connection with the Transaction, the legal, regulatory, tax, financial, accounting or other effects of a Transaction or the accuracy or completeness of the information contained in this presentation, and none of them shall have any liability based on or arising from, in whole or in part, any information contained in, or omitted from, this presentation or for any other written or oral communication transmitted to any person or entity in the course of its evaluation of the Transaction. This presentation contains information derived from third party sources, including research, surveys or studies conducted by third parties, information provided by customers and/or industry or general publications. While we believe that such third party information is reliable, we have not independently verified, and make no representation as to the accuracy of, such third party information. This presentation contains financial forecasts. These projections are for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. Important Information about the Transaction and Where to Find It Vesper Healthcare Acquisition Corp. (“Vesper Healthcare”) intends to file with the SEC a preliminary proxy statement of Vesper Healthcare in connection with the proposed Transaction and will mail a definitive proxy statement and other relevant documents to its stockholders. This presentation does not contain all the information that should be considered concerning the proposed Transaction and the other matters to be voted upon at the special meeting and is not intended to provide the basis for any investment decision or any other decision in respect of such matters. Vesper Healthcare’s stockholders and other interested persons are advised to read, when available, the preliminary proxy statement, the amendments thereto, and the definitive proxy statement in connection with Vesper Healthcare’s solicitation of proxies for the special meeting to be held to approve the proposed Transaction and other related matters, as these materials will contain important information about the Company and Vesper Healthcare and the proposed Transaction. The definitive proxy statement will be mailed to the stockholders of Vesper Healthcare as of a record date to be established for voting on the proposed Transaction and the other matters to be voted upon at the special meeting. Such stockholders will also be able to obtain copies of the proxy statement, without charge, once available, at the SEC’s website at http://www.sec.gov, or by directing a request to: Vesper Healthcare Acquisition Corp., 1819 West Avenue, Bay 2, Miami Beach, FL 33139. attention: [ Ɣ ] ([ Ɣ ]). Participants in the Solicitation Vesper Healthcare and its directors and officers may be deemed participants in the solicitation of proxies of Vesper Healthcare stockholders in connection with the proposed Transaction. Vesper Healthcare stockholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of Vesper Healthcare in its final prospectus for its initial public offering, which was filed with the SEC on September 30, 2020. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Vesper Healthcare stockholders in connection with the proposed Transaction will be set forth in the proxy statement for the Transaction when available. Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed Transaction and the other matters to be voted upon at the special meeting will be included in the proxy statement that Vesper Healthcare intends to file with the SEC.

Investment Criteria Has a leading position in an attractive and growing industry x Possesses scientific/brand differentiation, offers competitive advantages, and can benefit from additional capital and our experience x Ideal platform company to build a leading aesthetics technology company focused on estheticians and nurse practitioners x Exhibits significant long - term growth prospects and growth drivers x Partner with established management teams to achieve long - term strategic and operational excellence x Cash pay/no reimbursement risk x Platform for further acquisitions x Global commercial infrastructure in place with profitability x Offers the potential for an attractive risk - adjusted return for our stockholders x Can benefit from being, and is prepared to be, a publicly owned company x VESPER INVESTMENT THESIS: HYDRAFACIAL SATISFIES ALL KEY OBJECTIVES 3

VESPER & HYDRAFACIAL MANAGEMENT BRENT SAUNDE R S Co - Founder of Vesper Experience: 25 Years • Over 25 years of experience in various aspects of healthcare • Extensive M&A experience with over 80 strategic transactions completed • Most recently Chairman, President and CEO of Allergan • Will be Executive Chairman after business combination, and lead company strategy DR. MANISHA NARAS I M H AN Co - founder of Vesper Experience: 15 Years • Over 15 years of experience working with leading pharmaceutical and biotechnology companies • Most recently SVP of Strategic Initiatives, Portfolio Innovation and IR at Allergan (Ranked #1 by Institutional Investor for Best IR Professional, Best IR Team, and Best IR Program in the pharmaceuticals sector in 2020) • Will be CSO and oversee strategy and M&A CLINT CARNELL Chief Executive Officer Experience: 25 Years • Over 25 years of experience • CEO of HydraFacial since December 2016 • Previously founded and later successfully sold Charleston Renal Care to DaVita • Previous Head of Surgical for Bausch + Lomb, and was COO of Solta Medical with Thermage, Fraxel and Clear + Brilliant Brands L I Y UAN WOO Chief Financial Officer Experience: 23 Years • Over 20 years of experience • Recently joined HydraFacial in September 2020 • Prior to joining HydraFacial, was the COO and CFO of The VOID, a virtual reality entertainment company • Served as CFO for a number of companies such as SharkNinja, Gymboree, and bebe 4

THE HYDRA F ACIAL SIGNATURE TREATMENT 2 EX TRACT 3 HYDRATE 1 CLE A NSE 4 BOOST • Vortex cleaning and hydra peel exfoliation cleanses the skin and exfoliates the outermost layer, removing dead skin cells • Allows skin to reflect more light, inciting the “glow” EXTRACTION TIP • Non - irritant acid peel comprised of salicylic and glycolic acid loosens up pore debris and dirt • Extraction utilizes strong vacuum suction to remove blackheads and other impurities from the skin VORTEX FUSION TIP • Delivers Hyaluronic Acid, Peptides and other pro - antioxidant formulas into the skin • Detoxifies and rejuvenates, creating healthy skin structure and function BASE TIP UPGRADES BOOSTERS • Boosters are made to address specific skin concerns such as acne, hyperpigmentation, dry skin and wrinkles • HydraFacial has a number of proprietary boosters as well as partner boosters $200 Average cost M o n t h l y R eco mm ended frequency 30 Minute treatment 3 Core Seru m s 15 Bo o sters of which 8 are partner boosters 5

SKIN CORRECTION Medical delivery techno l og y - focused Lasers, Ultrasound, Fillers, Toxins SKIN CARE Daily, over - the - counter skin care Serums, Creams, Lotions, Supplements Highly effective, non - invasive and approachable treatment Bridging professional and retail skin care markets RESULTS SIMILAR TO A PROFESSIONAL MEDICAL TREATMENT AND THE EXPERIENCE OF A CONSUMER BRAND GAME CHANGING BRAND REDEFINING BEAUTY HEALTH BEAUTY HEALTH 6

CONSUMERS ARE INCREASINGLY WILLING TO SPEND ON HIGH END BEAUTY HEALTH GROWTH IN SKINCARE INDUSTRY DRIVEN BY PREMIUM MARKET AND EMPHASIS ON SKINCARE, RATHER THAN COSMETICS Source: Vogue Business; Industry interviews. MILLENNIALS AGING INTO CATEGORY • As millennials age, they are taking skincare more seriously and shifting spend to invest in premium treatments • Prefer to spend on experiences over products GROWTH IN DISPOSABLE INCOME • As U.S. economy grows, consumers have more disposable income to spend on premium products SHIFT IN SPEND FROM MAKEUP TO SKINCARE • Shift to treating underlying skin vs. using product to cover it up GROWTH IN MULTI - BRAND AND ONLINE RETAILERS • Multi - brand retailers (i.e. Sephora) and digital native brands captivating consumer and pushing innovation CONSUMERS SHOPPING ACROSS MASS AND PREMIUM • Consumers willing to shop across mass and premium in order to allocate more money towards trending categories/products 7 INFLUENCERS AND SOCIAL MEDIA DRIVING PURCHASE DECISIONS • Online demos, which originally gained popularity in cosmetics, are becoming increasingly influential in skincare • Skincare increasingly valued in age of selfies/social media

99% “Worth It” rating on RealSelf 48% 2019 YoY Sales growth 38% 2019 YoY Adjusted EBITDA growth 30 MIN, 3 STEPS TO CREATE LOYALTY AND DRIVE LIFETIME VALUE: CLEA N SE EXTRACT HY D R A TE $167M Sales 2019 $41M Adjusted EBITDA 2019 POWERFUL COMMUNITY ESTHETICI A N C O NSUMER 38 P a t en t s 18 pending patents 40 NPS Score among consumer (Higher than Botox ) 80 NPS Score among estheticians 51% 2019 Consumables (1) 49% 2019 Delivery Systems (1) Source: Third party research 2019; reflects pre - COVID conditions. Note: The above financial statements and projections are in draft form and based on internal financial reports as of November 12, 2020. These figures may not include all adjustments required by GAAP under PCAOB standards. The above figures include non - GAAP financial measures, including but not limited to Gross Margin, Adjusted Gross Margin and Adjusted EBITDA. Please see the corresponding reconciliation on slide 43 of this Presentation. (1) Excludes Shipping / Other Revenue. Based on 2019A. 8

Master Plan 9 1 Sell a lot of products and use that money to… 4 Leverage technology to connect them wherever, whenever & forever . 5 Build the ultimate flywheel of influence! 3 Find the consumers and build a direct relationship. 2 Invest in our skincare providers and use that relationship to…

BUSINESS OVE R VIEW 10

HYDRAFACIAL NPS RANKS HIGHEST ACROSS BRANDED AESTHETICS AND MEDTECH PEERS N 40 38 25 22 20 19 17 17 14 7 2 40 38 25 22 20 19 17 17 14 7 2 HydraFacial 1,007 Botox 220 CoolSculpt Lancôme Juvederm 174 343 169 Clear + Bri l liant 150 Estée L a uder 385 Dermal Inf u sion 151 Clinique Philosophy Origins 457 190 207 NPS Source: Third party research July 2019; reflects pre - COVID conditions. Note: NPS = Net Promoter Score as of 2019; Other brands listed are top 5 treatment and top 5 skincare brands used by HydraFacial users; N = Number of responses. 11

THE HYDRAFACIAL DELIVERY SYSTEMS AT A GLANCE CONS U MABLES AT A GLANCE 51% of Sales (1) • Serums flow through the delivery systems during a treatment, with a new set used with each system • A new tip is used for each step within the HydraFacial treatment • The systems allow for the option to customize treatments using different boosters 49% of Sales (1) • Developed in house using proprietary technology • Delivery systems have an average life of 7 years • 3.2M treatments performed annually (2) • 12% of practices/offices have more than 2 systems KERAVIVE SYSTEM PERK AT SEPHORA NEXT GENERATION SYSTEM: HUB OF ALL EXPERIENCES H Y DRAFACIAL BOOSTERS PARTNER BO O STERS TIPS SI G NA T URE Core Serums 1.0M Units Sold 8.8M Units Sold 55k Units Sold 21k Units Sold Source: Third party research 2019; reflects pre - COVID conditions. 1 Based on 2019A. Excludes Shipping / Other Revenue and Healthy Scalp. 2 Based on 2019A and includes Perk. Note: Units sold is based on 2019A. The above financial statements are in draft form and based on internal financial reports as of November 12, 2020. These figures may not include all adjustments required by GAAP under PCAOB standards. The above figures include non - GAAP financial measures, including but not limited to Gross Margin, Adjusted Gross Margin and Adjusted EBITDA. Please see the corresponding reconciliation on slide 43 of this Presentation. 12

Loved in 87 Countries Worldwide 15,000+ Delivery Systems LEADING PRESENCE AROUND THE GLOBE 13

INVESTMENT HIGHLIGHTS 14

MULTI - DIMENSIONAL GROWTH OPPO R T U NITIES 15 Source: Euromonitor research 2020. Note: TAM calculations consist of Skincare, Personal Care and Haircare markets. • Significant white space opportunity to grow units and consumables across geographies • Brand and product extensions • Technology driven product and category expansion PILLARS OF GROWTH EUROPE ASIA REST OF W O RLD 20 – 25% 15 – 20% 45 – 50% 10 – 15% Global Market Size $50 - 60B $150 – 200B FLYWHEEL OF INFLUENCE DRIVING A MASSIVE GLOBAL OPPORTUNITY MASSIVE OPPORTUNITY BOTH IN AND OUTSIDE THE US U.S.

16 $251 $201 $206 $212 $218 $217 $227 $235 $243 $77 $77 $77 $78 $78 $78 $79 $80 $82 $124 $129 $135 $140 $140 $149 $155 $162 $169 2016 2017 2018 2019 2020 2021 2022 2023 2024 S k i ncare Hair Care P A R TICI P A TING IN TWO HIGH - GROWTH CATEGORIES WITHIN PE R SON A L CARE SPA SERVICES GROWING ACROSS ALL TYPES OF TREATMENTS, PARTICULARLY IN FACIALS $0 .8 $0 .9 $1 .0 $1 .2 $1 .3 $1 .5 $1 .6 $1 .8 $2 .1 $2 .3 2 0 16 2 0 17 2 0 18 2 0 19 E 2 0 20 E 2 0 21 E 2 0 22 E 2 0 23 E 2 0 24 E 2 0 25 E 14.0% expected growth in U.S. skin care specialists (2016 – 2026) 11.1% expected growth in U.S. medical spa services (2017 – 2025) 6.4% expected growth in U.S. spa facilities (2017 – 2022) GLOBAL SKINCARE & HAIRCARE SALES ($B) U.S. MED SPA FACIAL TREATMENT SALES ($B) 13% CA G R 11% CAGR 2% CA G R 4% CA G R Source: Euromonitor 2020 and 2019. Note: Statistics for Global skincare & haircare reflect post - COVID conditions while all other data is from pre - COVID reports.

17 FAVORABLE MARKET SHIFTS BENEFITING THE HYDRAFACIAL BUSINESS MODEL Source: Third Party Research 2019; reflecting pre - COVID conditions. SKIN HEA L TH HYDRAFACIAL IS AN AND COMPANY NOT AN OR COMPANY EXPANDING DEM OG RAPHICS SIGNIFICANT O PP O R TUNI T Y ACROSS CHANNELS Today’s consumers are seeking approachable and effective skin health solutions that bridge the gap between OTC and invasive options Facial consumers are more diverse across genders and are younger than ever before, offering a significant market opportunity Consumers seek an experience across all channels of service 27% 32% 68% 43% 27% 41% 30% 32% 24% 13% Medical Light grad e t herap y skincare B a s ic f a c ial Micro derma - bra s ion Micro - Chemical needling peels Lasers Injectables Non - surgical face lifts Plastic s u r ger y NON - INVASIVE INVASIVE Spa Service Market Regular and $$ A e sthetics Market Occasional and $$$ Beauty Retail Market Often and $ 95% of HydraFacial customers use other treatments in a year ACROSS GENERATIONS ACROSS GENDERS ACROSS OTHER TREATMENTS Providers predict ~2x growth in male mix of total facial patients Over 30% of customers at beauty retailers (Ulta, Sephora, etc.) are under 24 20% of HydraFacial consumers receive 6+ other skincare treatments EXPANDING THE CATEGORY WHILE STILL BEING THE TREATMENT OF CHOICE FOR 45+ FEMALES

CREDIBLE NEAR - TERM PATH TO 12% OF U.S. POPULATION 18 Source: Third Party Research 2019; reflects pre - COVID conditions. (1) Per month spend does not include HydraFacial treatments. FACE SUPERS FACE REGULARS FACE CASUALS ~2% of total U.S. Adult Population ~4% of total U.S. Adult Population ~6% of total U.S. Adult Population USED HYDRAFACIAL USED HYDRAFACIAL USED HYDRAFACIAL 25% Received HydraFacial in past 12 months 7% Received HydraFacial in the past 12 months 1% Received HydraFacial in the past 12 months ~8 'facials’ per year 30 min per day face regimen Very strong motivations Si g n i fica n t 'life quests' ~5 'facials’ per year $50 per month skincare 30 min per day face regimen Strong m o t i v a t ions Si g n i fica n t 'life quests' ~1 'facials’ per year 15 min per day face regimen Mo d er a te motivations Mo d er a te 'life quests' $100 per month skincare (1) $20 per month s k incar e (1)

A DIFFEREN T I A T E D OFFERING B ENGAGED CONSU M ERS C PASSIONATE ES T H E T ICIANS D FAVORABLE SPA/CLINIC ECONO M ICS E GROWING DELIVERY SYSTEMS POWERFUL FLYWHEEL DRIVES COMPETITIVE POSITIONING 19 Source: Third party research 2019, reflecting Pre - COVID conditions. NPS as of 2019. Differentiated offering to build brand • Technologically advanced offering with high consumer and provider engagement • Customization/Personalization to skin concern A Strong base of engaged consumers to fuel growth • 50 – 60% Millennials (vs. ~40% of facial users), a highly - engaged demo • 15% of users get 4+ HydraFacial treatments in a given year • Industry - leading 40 NPS (vs. 5 – 15 NPS for other skincare brands) B Passionate esthetician community to recommend HydraFacial • Avid social discussion; 5x more esthetician posts than competitors • estheticians actively recommending (80 NPS; 45% of users learned about HydraFacial from their provider) • estheticians make ~20% more than from a traditional facial C • As HydraFacial grows, investing in training to build esthetician loyalty • Investing in targeted S&M investments to create deeply loved brand and R&D efforts to improve offering/create innovative products Favorable spa/clinic economics to increase HydraFacial share • Payback of delivery system in ~5 months Growing installed base to fund new investments E D

UNIQUE BUSINESS MODEL FOCUSED ON THE ESTHETICIAN 20 R EL A T IO N S H IP HOLDER WHAT’S IMPORTANT TO THE ESTHETICIAN VALUE IN THE ESTHETICIAN MODEL Training & C ontinued Education Access to Latest Technology & Products Loyal & Satisfied Returning Customers Marketing C apabilities 1 E DUC A T OR 2 INFLUENCER 3 SIMPLE & EFFICIENT CALL POINT – E S THET I CIAN BEAUTY RETAIL SPA SERVICES AES T HE T ICS

PROVIDER & ESTHETICIAN EDUCATION 21 *HFX best measure of success because of baseline of purchases & and few other influencers of behavior BOOST: business building workshop close to home Since June 2018; Acct/Attendee: 1,000/1,680 Business building Webinars JUMPSTART: fresh start for Blue Circles Since Mar 2019; Acct/Attendee:178/237 Consumables up 11% Podcast HFX*: 2 - day HF Experience Since April 2018; Acct/Attendee: 712/1,026 Consumables up 25 - 33% & $2M systems sold JOURNEY: exploring skin beyond the face Since Jan 2020; Acct/Attendee: 29/35 SPROUT: all about the scalp; launching a new service Since Feb 2020; Acct/Attendee: 42/48 Goal to be the world’s largest educator and deployer of estheticians Experience Center & Other Live Training On Demand, Quick Hits & Virtual Expert Hours 7 sessions year to date, avg >100 per session Program Rev. Opportunity $2500 x 500 $1.2M Staffing $6000 per Placement $6000 x 125 $750K “This is everything I wish I would have learned in aesthetics school.” Treatment Webinars Pilot: 293 enrolled; 229 active

SOCIAL MEDIA POWER HOUSE ~ 2.3 BILLION 2019 Media Impressions Significant World Tour ROI 170% ~230,000 Provider Searches in 2019 SIGNATURE EVENTS Note: reflects pre - COVID conditions. (1) Measured in 2019 IN THE PRESS 16% Instagram Engagement Rate Industry Leading (1) 22

200+ CO L LECTI V E YEARS OF EXPERIENCE within the sector LED BY A VISIONARY AND EXPERIENCED MANAGEMENT TEAM CLINT CARNELL Chief Executive Officer Experience: 25 Years MINGO KU VP & GM, APAC Experience: 22 Years ROSEMARIE HOLCOMB Senior Director, Marketing Communications Experience: 11 Years DAN WATSON EVP, Sales U.S. Experience: 36 Years DEB RODRIGUEZ Chief Talent Officer Experience: 33 Years MARK PRICE VP, RA, QA, R&D Experience: 35 Years JEFF KUCKENBAKER Chief Information Officer Experience: 20 Years LIYUAN WOO Chief Financial Officer Experience: 23 Years KATE GILBERT VP & GM, EMEA Experience: 30 Years LOURDES RUIZ VP, Operations Experience: 34 Years 23

Investment Highlights CATEGORY CREATING PRODUCT • Innovative product extension into IOT with data connection, personalization and clean beauty in skin and scalp health LEADING PLATFORM • Established, unique partnerships across many channels COMPELLING ECONOMIC PROFILE • High value and high margin equipment and consumables profile MU L T I - DIMENSIO N A L GROWTH OPPORTUNITIES • Digitally, categorically and globally; Organically and through M&A. Growth categories of, skin and scalp, consumable, and digital BEST - IN - CLASS MANAGEMENT AND BOARD • Highly - respected CEO, experienced executive management, and hands - on Vesper board EXCEPTIONAL MARKET O PP O RTUNI T Y • Connector capable of creating consumer demand around the globe UNIQUE BUSINESS MODEL • First industry mover with patented technology, brand following, partnerships across the ecosystem and innovative add - ons 1 2 3 4 5 6 7 24

GROWTH & FINANCIALS 25

STRATEGIC INITIATIVES RELENTLESSLY INNOVATE AS A CATEGORY CREATOR □ Category Ownership - Skin & Scalp Health □ 2.0 with personalized services to launch in 2022 □ Value - added innovation across all touchpoints – serums, devices, and experiences DRIVE CONSUMER DEMAND WITHIN THE ECOSYSTEM □ Turn up marketing of the brand, the wellness and personalization messaging □ Gift category with impactful promotional activities □ Focused investment in short - form and partnerships □ Continued effort with providers through education and pop - ups LEVERAGE TECHNOLOGY TO FUEL GROWTH END - TO - END □ Connector platform - Build robust and scalable programs that solidify relationship with estheticians & providers and end consumers □ Expand product offering digitally □ Data availability and personalized experiences EXPAND GLOBAL FOOTPRINT □ Sales offices with support □ Distributor to Direct M&A 26

HISTORICAL PERFORMANCE 27 – Continued domestic momentum combined with significant growth from recent international expansion – System upgrade cycle driven by the introduction of delivery systems in 2016 – Rapidly growing numbers of delivery systems with increasing recurring revenue in both the US and internationally • Growth in EBITDA driven by steady gross and adjusted EBITDA margins, largely a result of: – Continued increases in capital and consumable rep productivity KEY T AKE A W A Y S • Significant historical revenue growth driven by: $48 $66 $112 $167 '1 6 A '1 7 A '1 8 A '1 9 A $16 $17 $30 $41 '1 6 A '1 7 A '1 8 A '1 9 A NET SALES ($ IN MILLIONS) ADJUSTED EBITDA ($ IN MILLIONS) HF DELIVERY SYSTEMS (1) (UNITS) (1) Year - end delivery systems includes US and International. Note: The above financial statements are in draft form and based on internal financial reports as of November 12, 2020. These figures may not include all adjustments required by GAAP under PCAOB standards. The above figures include non - GAAP financial measures, including but not limited to Gross Margin, Adjusted Gross Margin and Adjusted EBITDA. Please see the corresponding reconciliation on slide 43 of this Presentation. 6,594 8,125 10,524 13,872 ' 1 6A ' 1 7A ' 1 8A ' 1 9A

8,679 9,286 9,834 10,524 11,218 1 2 ,0 5 2 12,829 13,872 14,421 1 4 ,4 9 5 15,124 Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20 HISTORICAL AND 2020A DELIVERY SYSTEMS 28 HF DELIVERY SYSTEMS (1) — 2018A THROUGH YTD 2020A (# UNITS) Achieved record total delivery systems in Q3 - 20 despite COVID - 19 KEY T AKE A W A Y S • Strong historical growth in delivery systems and number of consumable customers, with delivery systems increasing at a CAGR of ~24% from Q3 - 18 to Q3 - 20 – Despite significant impact of COVID - 19 in 2020, the number of HF delivery systems has continued to increase, both in the US and Internationally (1) Delivery systems include US and International. # of units calculated at the end of each period. Figures presented net of churn – a customer is assumed to be churned if they have not purchased any consumables in the last 18 months.

$11 $9 $14 $13 $13 $17 $12 $12 $15 $13 $12 $8 $1 $3 $9 $10 $9 $15 J an Feb M ar Apr M ay Jun Jul Aug Sep YTD 2020A MONTHLY PERFORMANCE (CONT’D) 29 KEY T AKE A W A Y S • 2020 monthly revenue is rebounding rapidly towards 2019 levels, demonstrating a strong recovery across the business – Quick ramp back to growth and profitability once locations are open and accessible – A number of domestic and international locations still significantly affected by opening restrictions, providing remarkable upside potential once restrictions are lifted – Monthly consumable customer volumes showing sequential monthly improvement, with Sept - 20 trending near prior year, pre - COVID - 19 levels – Sold 1400+ delivery systems since COVID - 19 (1) NET SALES YTD 2019A YTD 2020A ($ IN MILLIONS) Sales impacted by COVID - 19 with a quick recovery Note: The above financial statements are in draft form and based on internal financial reports as of November 12, 2020. These figures may not include all adjustments required by GAAP under PCAOB standards. The above figures include non - GAAP financial measures, including but not limited to Gross Margin, Adjusted Gross Margin and Adjusted EBITDA. Please see the corresponding reconciliation on slide 43 of this Presentation. (1) Represents the period from May 1, 2020 to November 12, 2020.

HISTORICAL AND PROJECTED FINANCIAL SUMMARY 30 Longer Term Outlook ($ IN MILLIONS) 2018A 2019A 2020E 2021E 2022E Net Sales $112 $167 $115 $181 $250 Sales Growth % 70 % 48 % (31)% 57 % 38 % Adj. Gross Profit $84 $125 $76 $133 $189 Adj. Gross Margin % 75% 75% 66% 73% 76% Adj. EBITDA $30 $41 $8 $25 $41 Adj. EBITDA Margin % 27% 25% 7% 14% 16% Note: The above financial statements and projections are in draft form and based on internal financial reports as of November 12, 2020. These figures may not include all adjustments required by GAAP under PCAOB standards. The above figures include non - GAAP financial measures, including but not limited to Gross Margin, Adjusted Gross Margin and Adjusted EBITDA. Please see the corresponding reconciliation on slide 43 of this Presentation.

TRANSACTION OVERVIEW ($ IN MILLIONS) 31 OWNERSHIP POST - BUSINESS COMBINATION ADDITIONAL TRANSACTION DETAILS • Pro forma enterprise value of $1.14bn • $350mm pipe raised at $10 per share • Transaction expected to close in the first half of 2021 Note: Assumes no redemptions from Vesper’s existing public shareholders. Excludes the impact of Vesper’s warrants. (1) Excludes any impact of earnouts. Sources Pro Forma Valuation (1) Vesper Cash in Trust $ 460 Share Price $10. 0 0 PIPE Investment 350 Pro Forma Shares Outstanding 124.0 Sellers Equity 315 Equity Value $ 1,240 Total $ 1,125 (+) Debt 0 ( - ) Pro Forma Cash (100) Uses Enterprise Value $ 1,140 Cash to Balance Sheet $ 100 37% 9% 28% 25% SPAC Shareholders PIPE Investment SPAC Management Shares Sellers Rollover Equity Debt Repayment 245 Sellers Equity 315 Secondary Proceeds 415 Estimated Transaction Costs & Expenses 50 Total $ 1,125

4.6x 5.7x 9.0x 5 . 9 x 6 . 9 x 5.3x 5.2x Hy d rafa c i a l In M o d e Al i gn Peloton L u l u l e m o n Median: 6.4x Median: 5.3x Median: 7.4x 20.6 % 43.0 % 29.0 % 21.1 % 7.7 % 9.4 % Hy d rafa c i a l In M o d e Al i gn Peloton L u l u l e m o n L 'O réa l Estée Lauder 2020E to 2022E Revenue CAGR Median: 24.8 % 47.4 % Median: 32.1 % Median: 8.5 % VALUATION BENCHMARKING HIGH GROWTH MEDICAL AESTHETICS, TRADITIONAL BEAUTY, AND CATEGORY CREATORS 32 Source: Cap IQ, IBES estimates as of 10 - Nov - 2020 2022E EV / Revenue L'Oréal Estée Lauder Traditional Beauty Medical Aesthetics Category Creators

APPENDIX 33

VESPER IS SUPPORTED BY A BEST IN CLASS BOARD OF DIRECTORS Board of Directors • Former Chairman, President and CEO of Allergan • Former CEO of Bausch & Lomb, Forest Labs, and Actavis Brent Saunders • Former SVP of Strategic Initiatives, Portfolio Innovation and IR of Allergan • Former Executive Director and head of IR of Regeneron Pharmaceuticals Dr. Manisha Narasimhan Barry Sternlicht Dr. Julius Warren Few Mr. Sternlicht is the Chairman & CEO of Starwood Capital Group, Chairman of Starwood Property Trust and Senior Advisor of Invitation Homes • 29 years of experience structuring investments with a combined asset value of over $110B • Founded Starwood Capital Group in 1991 • Built Starwood Hotels into one of the leading hotel and leisure companies in the world and the St. Regis Hotels brand into a global brand • Created W Hotels, one of the world’s most successful “boutique” brand • 30 years of medical experience, board - certified plastic surgeon for 18 years • Professor at the University of Chicago Pritzker School of Medicine and Former Developer and Director, Northwestern University Feinberg School of Medicine • Member of the American College of Surgeons and the American Society of Plastic and Reconstructive Surgery • Authored 100+ scientific publications Dr. Few is the Founder of The Few Institute For Aesthetic Plastic Surgery Michael Capellas • More than 30 years in executive, senior leadership, management, and advisory roles in IT and Telco • Former President of Hewlett - Packard, former CEO of Compaq, MCI Inc. (previously WorldCom), First Data Corporation and VCE • Founding Chairman and CEO of VCE, a joint venture between Cisco, EMC and VMware which developed and commercialized an innovative platform for cloud computing Mr. Capellas currently serves on the Boards of Cisco, Flex, and Blue Yonder 34

VESPER AND HYDRAFACIAL ARE STRENGTHENED BY ADVISORS Desiree Gruber is a Peabody Award - winner and was the co - founder and executive producer of the Project Runway television series for 16 years. She’s now the founder of Full Picture, a brand accelerator, content production, communications, and consulting services company. Bob Perry Robert Perry has over thirty years’ experience in the medical device industry and from 2013 to 2020 served as the Sr. Vice President of Device R&D at Allergan with responsibility for Aesthetic and Eyecare products. While at Allergan, Mr. Perry played a leadership role in the assessments and integrations of numerous acquisitions. Sachin M. Shridharani, MD, FACS Dr. Sachin Shridharani is a renowned, Manhattan based plastic surgeon board certified by The American Board of Plastic Surgery. He is the founder of LUXURGERY and the first plastic surgeon in New York to inject Kybella following its FDA approval. He has since performed nearly three thousand treatments. Vesper Advisory Board HydraFacial Advisors Desiree Gruber Joe Pine Joseph Pine II is an internationally acclaimed author, speaker, and management advisor to Fortune 500 companies and entrepreneurial start - ups alike. Mr. Pine's experiences prior to co - founding Strategic Horizons include holding a variety of technical and managerial positions with IBM. Jane Christensen Jane Christensen is the co - founder and President of Omni providing business strategies for medical practices and retail integration of Omni’s bioceutical products. Her most entrepreneurial recent ventures include: Omni Medical Imaging, a spa like out - patient radiology center; Omni Wellness Center; and Integrated Laser Solutions Eddie Yoon Eddie Yoon is the founder of EddieWouldGrow, LLC, a think tank and advisory firm on growth strategy. Previously he was one of the senior partners at The Cambridge Group, a strategy consulting firm. 35

EVOLUTION OF THE HYDRAFACIAL STORY 36 MORE THAN TRIPLED THE BUSINESS FROM $48M NET SALES IN 2016 TO $167M IN 2019 CREATING AND DEFINING A CATEGORY (2017 – 2019) BUILDING A PRODUCT COMPANY (1997 – 2016) PLAYING OFFENSE DURING COVID (2020) U N LEASHING THE BRAND DIRECT TO CONSUMER (2021 and Beyond) Note: The above financial statements and projections are in draft form and based on internal financial reports as of November 12, 2020. These figures may not include all adjustme nts required by GAAP under PCAOB standards. The above figures include non - GAAP financial measures, including but not limited to Gross Margin, Adjusted Gross Margin and Adjusted EBITDA. Please see the corresponding reconciliation on slide 43 of this Presentation.

37 HYDRAFACIAL’S COMPETITIVELY DIFFERENTIATED PRODUCT CREATES CONSUMER PULL AND PROVIDER PUSH Source: Third party research July 2019; reflects pre - COVID conditions. Note: NPS = Net Promoter Score as of 2019; Other brands listed are top 5 treatment and top 5 skincare brands used by HydraFacial users. (1) As of Q3 2020. HydraFacial’s TRULY DIF F ERE N T IA T ED PRODUCT with a technological edge… • Unique product in the market that meets consumer expectations • Technology is protected by 20+ years of R&D and 38 patents • 15K+ active delivery systems (1) …leads to strong brand creating 'PULL' DEMAND FROM CONSUMERS • Immediate benefits, limited downtime and less pain than manual extractions • Immediate results from a 30 - minute treatment • 99% “Worth It” rating on Real Self • High awareness and NPS as the only branded facial in market …and a strong reputation with PROVIDERS TO 'PUSH' DEMAND • Favorable economics for spa owners and estheticians • Strong existing community of estheticians • Best - in - class 80 NPS from estheticians

38 GROWING PORTFOLIO OF LEADING PARTNERSHIPS (2 0 1 9 ) (2 0 1 8 ) (2 0 1 8 ) (2 0 1 7 ) (2017 protocol) (2 0 1 8 ) (coming 2021) (2 0 1 9 ) MEDICAL/MED SPA SPAS/RESORTS PARTNER BOOSTERS BEAUTY RETAIL Spas operated by nurse practitioners, estheticians and PAs overseen by physicians, as well as plastic surgeon and dermatology practices that offer cosmetic treatments Day, wellness, hotel and destination spas typically operated by estheticians Retail beauty products stores that also offer skincare treatments on a limited basis + (2 0 2 0 )

8, 1 25 1 0 ,5 2 4 1 3 ,8 7 2 1 5 ,1 2 4 '17 '18 '19 Q3 '20 RECURRING NATURE OF BUSINESS MODEL 39 • Once installed, systems generate meaningful recurring revenue • 51% of 2019 revenue from consumables and expected to grow over time as installed base expands • Consumables grow as utilization increases post COVID on existing and newly installed systems and as boosters increase revenue per treatment • Attractive economics for med spa owners and estheticians KEY POINTS HydraFacial’s delivery systems numbered 15,124 in Q3 2020 • Achieved record total delivery systems achieved in Q3 - 20 despite COVID HYDRAFACIAL DELIVERY SYSTEMS (1) Source: Third party research 2019; reflects pre - COVID conditions. (1) Year - end delivery systems includes US and International.

PLAYING OFFENSE DURING COVID AND BUSINESS RECOVERY 2020 MONTHLY REVENUE HAS REBOUNDED RAPIDLY TOWARDS 2019 LEVELS 40 CREATIVE RES P ONSES INITIAL IMPACT IMPROVING ENV I RO N MENT STATE OF B U S I NESS □ Managed business steadily through COVID □ Contained impact of salon and store closures to Spring 2020 □ Monthly revenue declined to low single digit millions □ Initiated inventive solutions to drive revenue □ Integrated and streamlined operations at the new Burnett facility □ Launched Keravive scalp treatment program □ Invested in long term growth opportunities □ Launched warehouse management system □ Quickly ramped up following store reopenings □ Began rehiring sales team □ 600 + increase in delivery systems in Q 3 - 20 despite COVID - 19 □ 2020 monthly revenue has rebounded rapidly towards 2019 levels □ Some locations are still limited by opening restrictions, providing upside potential once lifted □ Vast majority of sales organization able to be rehired after furlough

HYDRAFACIAL CURRENT OWNERS • Chicago - based private equity firm focused exclusively on the healthcare industry • One of the country’s largest dedicated healthcare private equity firms, having invested over $2 billion and raised nearly $3 billion of commitments since founding • Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program • Highly respected private equity firm focused exclusively on the healthcare industry, primarily making control investments in North American middle - market healthcare companies • Currently manages over $1.4 billion in committed capital and invests in leading healthcare companies with proven management team • Specializes in helping mid - stage companies reach their growth potential by providing the capital, deep industry knowledge, strategic guidance and acquisition expertise 41

HISTORICAL INCOME STATEMENT ($ IN MILLIONS) 42 Note: The above financial statements are in draft form and based on internal financial reports as of November 12, 2020. These figures may not include all adjustments required by GAAP under PCAOB standards. The above figures include non - GAAP financial measures, including but not limited to Gross Margin, Adjusted Gross Margin and Adjusted EBITDA. Please see the corresponding reconciliation on slide 43 of this Presentation. Fiscal Year Ending December 31 2018A 2019A Net Sales $112 $167 Sales Growth % 70 % 48 % COGS $29 $49 Adj. Gross Profit $84 $125 Adj. Gross Margin % 75% 75% Adj. EBITDA $30 $41 Adj. EBITDA Margin % 27% 25%

2018 AND 2019 ADJUSTED EBITDA BRIDGE ($ IN MILLIONS) 43 Source: Company Financials. (1) Quarterly and transaction related management fees paid to private equity sponsors, board of director fees and expenses. Note: The above financial statements are in draft form and based on internal financial reports as of November 12, 2020. These figures may not include all adjustments required by GAAP under PCAOB standards. The above figures include non - GAAP financial measures, including but not limited to Gross Margin, Adjusted Gross Margin and Adjusted EBITDA. Operating Income $ 11 $ 14 Depreciation/Amortization 11 14 Management and board costs 4 2 (1) Non - recurring and one - time fees 4 11 Adjusted EBITDA $ 30 $ 41 Operating Income to Adjusted EBITDA Bridge 2018 2019